Last Updated: November 18, 2026

List of Excipients in Branded Drug DONEPEZIL HYDROCHLORIDE

« Back to Dashboard


Donepezil Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: October 17, 2026

Donepezil hydrochloride is a mature acetylcholinesterase inhibitor with extensive generic competition in oral tablets and orally disintegrating tablets. The primary commercial opportunity is not a new chemical entity strategy. It is differentiated delivery: orally disintegrating systems, multiparticulates, abuse-resistant or adherence-oriented packaging, and transdermal delivery. Excipient selection should prioritize dose uniformity, rapid disintegration, taste control, moisture stability, manufacturability, and regulatory familiarity.

The main U.S. dosage forms are 5 mg and 10 mg immediate-release tablets, 5 mg and 10 mg orally disintegrating tablets, and the 7-day transdermal system marketed as Adlarity. Aricept and its historical patent estate no longer provide a meaningful composition-of-matter barrier to generic entry. The strongest remaining intellectual-property opportunities are formulation, delivery-system, manufacturing, device, and combination claims.

What is the FDA regulatory status of donepezil hydrochloride?

Donepezil hydrochloride is FDA-approved for the treatment of dementia associated with Alzheimer’s disease. FDA-approved oral products include immediate-release tablets and orally disintegrating tablets. A transdermal donepezil system, Adlarity, was approved in 2022 for once-weekly administration in patients with mild, moderate, or severe dementia associated with Alzheimer’s disease (FDA, 2022a).

Product category Typical strengths or delivery U.S. regulatory status Commercial position
Immediate-release tablets 5 mg, 10 mg Generic ANDA products widely marketed Lowest-cost, highest-competition segment
Orally disintegrating tablets 5 mg, 10 mg Generic and branded ODT products Differentiation through adherence and swallowing convenience
Aricept tablets 5 mg, 10 mg Originator product; generic competition Mature, largely genericized
Aricept 23 mg Extended-release/high-dose tablet Originator high-dose product More limited competition and higher tolerability burden
Adlarity patch 5 mg/day and 10 mg/day, once weekly FDA-approved transdermal system Premium adherence-oriented segment
Compounded liquid Variable Pharmacy-compounded, not equivalent to an FDA-approved commercial product Niche, caregiver-driven demand

Donepezil is a small molecule, not a biologic. Biosimilar regulation does not apply. Competitive risk comes from generic ANDAs, alternative formulations, and delivery systems rather than biosimilar substitution.

What excipients are used in donepezil hydrochloride tablets?

Commercial tablet excipients commonly include microcrystalline cellulose, lactose, starch or modified starch, crospovidone, croscarmellose sodium, magnesium stearate, talc, hypromellose, polyethylene glycol, titanium dioxide, and colorants. The exact composition depends on the manufacturer and dosage form and should be confirmed against the current product label or DailyMed listing.

Excipient functions in immediate-release tablets

Formulation function Common excipient classes Strategic objective
Dilution and compressibility Microcrystalline cellulose, lactose, mannitol, dibasic calcium phosphate Maintain tablet weight and mechanical strength
Disintegration Crospovidone, croscarmellose sodium, sodium starch glycolate Achieve rapid release without excessive friability
Lubrication Magnesium stearate, sodium stearyl fumarate Prevent sticking and improve ejection
Granulation and binding Povidone, pregelatinized starch, hydroxypropyl cellulose Improve flow and tablet integrity
Film coating Hypromellose, polyethylene glycol, polyvinyl alcohol Improve appearance, swallowability, and handling
Opacity and color Titanium dioxide, iron oxides, approved lake colors Product identification and light protection
Taste masking Coating polymers, ion-exchange resins, sweeteners, flavors Improve ODT and liquid acceptability
Moisture control Low-moisture fillers, desiccant packaging, moisture-barrier films Protect stability and preserve disintegration performance

Donepezil hydrochloride is used at a relatively low dose, so excipient selection affects blend uniformity. Low-dose uniformity is a central technical issue in direct compression. A formulation with poor flow or segregation can create content-uniformity failures even when the active pharmaceutical ingredient is inexpensive and chemically stable.

What excipients are best for donepezil orally disintegrating tablets?

The most commercially relevant ODT strategy combines a porous or rapidly wettable matrix with taste control and adequate mechanical strength. Mannitol is frequently attractive because it provides a cooling mouthfeel, acceptable compressibility, and low hygroscopicity relative to some polyols. Crospovidone and croscarmellose sodium can accelerate water uptake, while aspartame, sucralose, acesulfame potassium, flavors, or polymeric taste-masking systems can reduce bitterness.

ODT design priorities

  1. Disintegration time: The tablet should disperse quickly in saliva without requiring water.
  2. Taste: Bitterness can reduce caregiver acceptance and patient adherence.
  3. Mechanical strength: The tablet must withstand packaging, shipping, and removal from unit-dose systems.
  4. Moisture resistance: Hygroscopic excipients can cause softening, sticking, or delayed disintegration.
  5. Dose uniformity: A low drug load increases sensitivity to segregation and mixing performance.
  6. Packaging compatibility: Blister packaging may be preferable to high-moisture bottles.

A practical ODT platform may use mannitol or a mannitol-cellulose matrix, a superdisintegrant, a low-level binder, a lubricant selected for rapid wetting, and a taste-masking layer or particulate intermediate. The formulation should avoid excessive hydrophobic lubrication because it can slow wetting and dissolution.

Which taste-masking technologies are commercially attractive?

Three approaches have the strongest commercial rationale:

  • Polymer-coated drug particles: Useful when bitterness is pronounced and the coating remains intact during handling but releases rapidly at gastrointestinal pH.
  • Ion-exchange resin complexes: Can reduce immediate taste exposure, although resin capacity, drug loading, release kinetics, and excipient qualification must be controlled.
  • Multiparticulate ODTs: Pellets or microcapsules can combine taste masking with modified release, but they introduce more manufacturing steps and content-uniformity risks.

A simple sweetener-and-flavor approach has the lowest cost but may provide insufficient masking for sensitive patients. A coated-particle approach has higher development and scale-up costs but offers stronger formulation differentiation.

What excipient strategy supports a liquid donepezil product?

A ready-to-use oral solution or suspension could address patients who cannot swallow tablets, but it faces a more demanding stability and packaging profile. Key issues include pH control, microbial preservation, precipitation, adsorption to packaging, dosing-device accuracy, and taste.

Liquid formulation opportunities

A commercial liquid product could use:

  • A buffered aqueous vehicle.
  • A sweetener system suitable for chronic administration.
  • A flavor system compatible with the active and preservative.
  • A validated preservative or preservative-free unit-dose packaging.
  • A calibrated oral syringe or dosing cup.
  • A child-resistant closure and tamper-evident packaging.

A suspension can improve taste masking by keeping coated drug particles out of solution, but it requires controlled particle size, redispersibility, sedimentation performance, and shake-volume instructions. A solution is simpler for dose delivery but exposes the dissolved drug to the taste receptors and may require stronger flavor masking.

The strongest commercial use case is caregiver administration in advanced dementia. The product would compete against tablet crushing, pharmacy compounding, and caregiver workarounds. Regulatory value would depend on demonstrated dose accuracy, stability, palatability, and meaningful convenience.

What formulation patents can protect donepezil products?

The original donepezil composition-of-matter protection has expired. New protection must generally focus on a specific formulation or delivery architecture.

Potential claim categories

Claim category Examples of protectable subject matter Relative strength
ODT composition Defined excipient ratios, porosity, disintegration profile, taste-masked particles Moderate if technically narrow and well supported
Multiparticulate system Coated pellets, resin complexes, particle-size limits, release profiles Moderate to strong when difficult to design around
Oral liquid pH, preservative system, solubilizer, stability profile, dosing system Moderate
Transdermal formulation Drug-in-adhesive matrix, permeation enhancer, backing layer, release liner Stronger when linked to device performance
Manufacturing process Granulation, coating, drying, compression, particle engineering Narrow but commercially useful
Packaging Moisture-barrier blister, unit-dose dispensing, adherence packaging Usually narrower and easier to design around
Method of use Improved adherence, reduced nausea, caregiver administration, dosing conversion Variable; clinical support is important
Combination product Donepezil with another active or device Depends on clinical and regulatory positioning

A patent should claim measurable technical features rather than merely listing familiar excipients. Examples include rapid disintegration under defined test conditions, reduced bitterness measured through an established panel method, improved humidity stability, controlled transdermal flux, or a defined in vitro-in vivo release relationship.

What is the Orange Book status and patent expiration history for Aricept?

Aricept was developed by Eisai and commercialized with Pfizer. The original donepezil patent estate has expired, and generic donepezil entered the U.S. market in 2010. Historical Aricept patent protection included the donepezil compound patent and later formulation or dosage-related protection. Those patents are no longer a practical barrier to standard generic 5 mg and 10 mg immediate-release tablets.

The FDA Orange Book remains the controlling source for current listed patents, exclusivity, and reference-listed-drug information (FDA, 2024a). The key commercial point is that conventional donepezil tablets do not depend on an active originator composition-of-matter monopoly.

Current exclusivity assessment

Exclusivity or barrier Current relevance
New chemical entity exclusivity Expired
Original compound patent Expired
Standard tablet formulation patents Historical protection has expired
Pediatric exclusivity Historical period, expired
23 mg high-dose product protection Reduced by age of product and generic competition; current listings require Orange Book confirmation
Transdermal system patents Potentially relevant to Adlarity and its delivery architecture
ODT patents Historical or product-specific; no broad barrier to ODT development
Manufacturing know-how May remain valuable as trade secret even when patent protection is absent

When does donepezil lose exclusivity?

Donepezil lost its principal U.S. market exclusivity before generic entry in 2010. The standard oral tablet market is therefore post-exclusivity. New products can still obtain limited protection through formulation patents, method-of-use patents, device patents, or three-year exclusivity for certain new clinical investigations supporting a new dosage form or indication.

The timing for a new product depends on its regulatory pathway:

Product strategy Likely regulatory route Main exclusivity or IP lever
Conventional tablet ANDA Bioequivalence and low-cost manufacturing
ODT equivalent ANDA or 505(b)(2), depending on reference and differences Formulation patent, limited regulatory exclusivity if eligible
New oral liquid 505(b)(2) or ANDA, depending on product relationship Clinical bridging, formulation claims
New transdermal product 505(b)(2) or NDA Delivery-system patents and possible regulatory exclusivity
Fixed-dose combination 505(b)(2) or NDA Combination patent and clinical data
Adherence package ANDA supplement or product-specific pathway Packaging claims and commercial differentiation

Which companies are challenging or competing with donepezil products?

Generic competition includes large and mid-sized ANDA manufacturers, contract manufacturers, and regional suppliers. The standard tablet segment is highly fragmented and price-sensitive. The major branded delivery-system competitor is Corium’s Adlarity patch.

Competitor type Representative products Competitive basis
Generic tablet manufacturers Donepezil HCl 5 mg and 10 mg tablets Price, supply reliability, formulary access
Generic ODT manufacturers Donepezil ODT 5 mg and 10 mg Swallowing convenience and caregiver preference
Originator oral products Aricept and high-dose Aricept 23 mg Brand recognition, historical prescriber familiarity
Transdermal developer Corium, Adlarity Weekly dosing and reduced daily pill burden
Compounding pharmacies Liquid or altered dosage forms Individualized administration, not FDA-approved commercial equivalence
Combination-product developers Donepezil with device or adjunctive therapy Differentiated adherence or disease-management positioning

No biosimilar competitor exists because donepezil is not a biologic. Paragraph IV activity is most relevant to any later-listed patent covering a newer formulation, particularly a transdermal system or high-dose product, rather than to ordinary generic tablets.

What patent litigation and settlement risks affect donepezil?

The main historical litigation risk concerned generic entry against Aricept-related patents. That risk has largely passed for standard oral products. Current litigation exposure is more likely to arise from:

  • A Paragraph IV certification against a listed patent for a transdermal product.
  • Patent disputes over a high-dose or modified-release formulation.
  • Trade-secret claims involving transdermal manufacturing or coating processes.
  • Device patents covering patch construction, adhesive systems, or drug delivery.
  • Patent-owner allegations that an ODT or taste-masked product falls within a formulation claim.

A settlement could delay launch, impose supply or licensing conditions, or permit an authorized generic. For a new entrant, the most important diligence points are the current Orange Book listings, FDA patent certifications, pending district-court cases, and any inter partes review involving the relevant formulation or device patents.

How strong is the patent estate for donepezil formulation products?

The patent estate is weak for conventional tablets and stronger for technically complex delivery systems.

Conventional tablets

A basic immediate-release tablet using standard fillers, binders, disintegrants, and lubricants is difficult to protect broadly. The likely commercial strategy is cost leadership, reliable supply, and a simple regulatory pathway.

ODT products

ODTs can support stronger claims when they include:

  • A defined taste-masked particle architecture.
  • A specific disintegration and dissolution profile.
  • A low-moisture formulation with demonstrated stability.
  • A manufacturing process that controls particle distribution and content uniformity.
  • A packaging system that preserves performance.

The risk is obviousness. Many standard ODT excipients and processing methods are well known, so claims must link composition to a measurable performance improvement.

Transdermal products

Transdermal delivery has the strongest formulation and device differentiation because it requires control of drug loading, adhesive behavior, skin permeation, flux, irritation, residual drug, and seven-day wear performance. Excipient and adhesive choices can create meaningful manufacturing know-how even where patent claims are narrow.

What manufacturing and intellectual-property barriers exist?

Donepezil tablets are relatively straightforward to manufacture. The main barriers are operational:

  • Uniform distribution of a low-dose active.
  • Prevention of blend segregation.
  • Control of lubricant concentration and mixing time.
  • Stable ODT production under humidity exposure.
  • Consistent film coating and color matching.
  • Supply of qualified excipients.
  • Packaging that protects tablets from moisture.
  • Bioequivalence across scale-up batches.

The barriers increase for taste-masked multiparticulates and transdermal systems. Coating uniformity, residual solvent control, particle-size distribution, adhesive rheology, permeation testing, and long-term stability become central. These processes can be protected through patents, confidential manufacturing parameters, supplier qualification, and analytical methods.

What commercial opportunities exist for donepezil excipients?

Low-cost generic tablet platform

The lowest-risk opportunity is an optimized direct-compression platform using widely accepted excipients. Value comes from:

  • High-throughput manufacture.
  • Low tablet weight.
  • Robust content uniformity.
  • Minimal coating complexity.
  • Standardized excipient sourcing.
  • Low packaging cost.

This strategy supports price competition but offers limited patent value.

Premium ODT platform

An ODT platform can support higher margins if it delivers rapid disintegration and acceptable taste without special handling. Commercial differentiation is strongest in patients with dysphagia and in caregiver-administered settings.

The preferred excipient strategy is a low-moisture, mannitol-based matrix with a superdisintegrant and a taste-masking intermediate. Unit-dose blister packaging can reinforce the product position.

Oral liquid platform

A ready-to-use liquid could compete in institutional care, home care, and advanced dementia. The commercial advantage is administration flexibility. The principal development risk is palatability and preservative or container compatibility.

Weekly transdermal platform

The weekly patch is the clearest premium opportunity. A competing system would need to show reliable adhesion, acceptable skin tolerability, consistent donepezil delivery, and an economic advantage. It would also face stronger patent and device scrutiny than a tablet or ODT.

Excipient supplier opportunity

Excipient manufacturers can create value by offering:

  • Co-processed ODT excipients.
  • Taste-masking polymers or resin systems.
  • Low-moisture direct-compression blends.
  • Adhesive matrices for transdermal delivery.
  • Functional packaging materials.
  • Ready-to-use formulation platforms supported by regulatory documentation.

A supplier with strong drug-product development data can capture formulation-design work rather than compete solely on excipient price.

How does donepezil compare with competing Alzheimer’s drugs?

Donepezil differs from newer anti-amyloid antibodies because it is an established symptomatic treatment delivered mainly by oral or transdermal routes. It has no biosimilar pathway, no infusion-center requirement, and low active-ingredient cost. Its commercial challenge is generic commoditization, not high manufacturing cost.

Attribute Donepezil hydrochloride Anti-amyloid biologics
Molecule type Small molecule Monoclonal antibody
Main regulatory competition Generics and reformulations Biosimilars and follow-on biologics
Administration Tablet, ODT, patch Intravenous infusion for leading products
Excipient opportunity Taste masking, disintegration, adhesion, packaging Protein stabilization, aggregation control, infusion compatibility
Patent focus Formulation, device, method, process Composition, sequence, formulation, manufacturing, use
Commercial barrier Low-cost generic substitution Clinical infrastructure, monitoring, reimbursement

Donepezil’s lower technical complexity creates a crowded base market. The commercial premium must come from adherence, caregiver convenience, tolerability, or delivery performance.

What generic launch scenarios exist for donepezil products?

Scenario 1: Additional standard tablets

This is the fastest and lowest-risk route. It offers limited differentiation and exposes the applicant to aggressive price competition.

Scenario 2: ODT launch

An ODT can command better positioning if the product has reliable taste masking, robust packaging, and a clear caregiver-use proposition. The main risks are formulation patent scope and proving equivalence where the dosage form differs from the reference product.

Scenario 3: High-dose or modified-release product

A 23 mg or modified-release product may offer higher value per prescription but has greater tolerability, bioequivalence, and patent risk. The patient population is narrower than for 5 mg and 10 mg therapy.

Scenario 4: Transdermal competitor

A weekly patch could pursue a 505(b)(2) strategy. The product would require substantial development work and may face active device and formulation patents. It offers the greatest potential differentiation but also the highest capital requirement.

Scenario 5: Caregiver-focused liquid

A liquid product could target long-term-care facilities and home caregivers. Packaging, dosing accuracy, palatability, and supply reliability would be as important as the excipient formula.

Key Takeaways

  • Donepezil hydrochloride is a mature, genericized small molecule with no biosimilar risk.
  • Standard 5 mg and 10 mg tablets are primarily cost-competition products.
  • ODTs offer the most practical formulation opportunity through taste masking, rapid disintegration, and moisture-protective packaging.
  • Oral liquids can address dysphagia and caregiver administration but require strong stability, palatability, and dosing controls.
  • Transdermal delivery offers the highest differentiation and patent value, with higher development and litigation risk.
  • Broad excipient patents are difficult to obtain because common tablet and ODT excipients are well known.
  • Stronger protection requires defined composition ranges linked to measurable performance or a technically complex delivery system.
  • Historical Aricept exclusivity has expired for conventional oral products.
  • Current diligence should focus on Orange Book listings and patent activity relating to newer dosage forms, especially transdermal systems and high-dose products.
  • Excipient suppliers can compete through co-processed ODT platforms, taste-masking systems, low-moisture blends, adhesive matrices, and regulatory-ready development packages.

FAQs

Can donepezil hydrochloride be formulated with lactose?

Yes. Lactose is used as a tablet diluent in many immediate-release products, subject to product-specific compatibility, dose uniformity, moisture, and patient-labeling considerations.

Which excipient is best for a donepezil ODT?

No single excipient is universally optimal. Mannitol is often attractive as a bulk filler, while crospovidone or croscarmellose sodium can support rapid disintegration. Taste masking and packaging determine commercial performance.

Is donepezil hydrochloride suitable for a transdermal patch?

Yes. The FDA-approved Adlarity patch demonstrates clinical and regulatory feasibility for weekly transdermal donepezil delivery. A competing product would require controlled flux, skin tolerability, adhesion, and device performance.

Can a generic company obtain new exclusivity for a donepezil formulation?

Potentially. A qualifying new dosage form, clinical investigation, formulation, or delivery system may support patent protection and, depending on the regulatory pathway, limited regulatory exclusivity. The scope depends on the specific FDA submission and patent claims.

Does donepezil have current Paragraph IV risk?

Standard oral donepezil tablets face mature generic competition, so the principal Paragraph IV risk is associated with later-listed patents covering newer products, including transdermal, modified-release, high-dose, or combination formulations.

References

  1. Corium, Inc. (2022). Adlarity (donepezil) transdermal system prescribing information. U.S. Food and Drug Administration.

  2. DailyMed. (2024). Donepezil hydrochloride tablet and orally disintegrating tablet labeling. U.S. National Library of Medicine.

  3. U.S. Food and Drug Administration. (2022a). FDA approves first once-weekly transdermal system for treatment of Alzheimer’s disease dementia. https://www.fda.gov

  4. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov

  5. U.S. Food and Drug Administration. (2024b). Inactive ingredient database. https://www.accessdata.fda.gov

  6. U.S. Pharmacopeia. (2024). General chapter <701> disintegration and related dosage-form testing. United States Pharmacopeial Convention.

  7. U.S. Food and Drug Administration. (1996). Aricept approval history and prescribing information. https://www.accessdata.fda.gov

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.